Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05535829
Other study ID # RENJIFHRCC
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date August 1, 2022
Est. completion date December 1, 2024

Study information

Verified date August 2023
Source RenJi Hospital
Contact Yunze Xu
Phone +8618801967501
Email xuyunze@renji.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) is a rare subtype of RCC characterized by germline/somatic mutation of the fumarate hydratase (FH) gene, and is an extremely aggressive tumor, with a propensity to disseminate early even in the setting of a small primary tumor. This project is a real-world exploratory study aiming to explore potential molecular markers detectable at baseline that can enable the prediction of clinical efficacy of systemic treatments in advanced FH-deficient RCC. This project is a real-world exploratory study aiming to explore potential molecular markers detectable at baseline that can enable the prediction of clinical efficacy of immunotherapy combined with target therapy in advanced FH-deficient RCC. This study aims to include a total of 100 patients initially diagnosed with advanced FH-deficient RCC. Paired tissue and blood samples collected from all patients before or/ and after the start of immunotherapy-based treatment (at diagnosis or/ and their change with treatment) will be analyzed. The patient samples will be submitted for molecular analysis, including next-generation sequencing (NGS)-based gene expression profiling (GEP), RNA-sequencing, multiplex immunofluorescence staining and inflammation-related T-cell receptor (TCR) repertoire profiling, ect. The molecular assay results will include but will not be limited to tumor mutation burden (TMB), microsatellite instability (MSI) status, DNA damage repair (DDR)-related gene mutation status, and programmed death-ligand 1 (PD-L1) expression level. Patients will be followed-up for treatment responses until radiological confirmation of disease progression to immunotherapy-based treatment. The molecular assay results will then be analyzed with clinical data including objective responses and progression-free survival outcomes, among others, to identify molecular markers at baseline that are associated with clinical efficacy of immunotherapy-based treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 1, 2024
Est. primary completion date December 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. =18 years old; 2. histopathological evidence of FH-deficient RCC, which was confirmed by Sanger or next-generation sequencing after initial screening by IHC. 3. included patients must be diagnosed with metastatic renal cell carcinoma or have a TNM stage IV (according to 2009 TNM Classification); 4. new FH-deficient RCC patients who has scheduled to start 1st cycle of systemic treatment; 5. ECOG score =2; 6. life expectancy = 3 months; 7. sign informed consent, and be able to follow the visit and related procedures stipulated in the program; 8. agree to collect tumor tissue, blood and other specimens required by this study and apply them to relevant studies; Exclusion Criteria: 1. patients with other malignant tumors with different primary sites or histology from the tumor evaluated in this study within 2 years of personal history. 2. major surgery or severe trauma within 4 weeks before enrollment; 3. known or suspected active autoimmune diseases (congenital or acquired), such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, thyroiditis, etc. Patients with type 1 diabetes with good insulin control can also be enrolled. 4. known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation; 5. allergic to any component of monoclonal antibody; 6. suffering from other uncontrolled serious diseases, including but not limited to: A) severe infection in the active phase or clinically poorly controlled; B) HIV infection (HIV antibody positive); C) acute or chronic active hepatitis b (HBsAg positive and HBV DNA>1*103/ml) or acute or chronic active hepatitis c (HCV antibody positive and HCV RNA>15IU/ml); D) active tuberculosis, etc.; 7. class iii-iv congestive heart failure (New York heart association classification), poorly controlled and clinically significant arrhythmia; 8. uncontrolled arterial hypertension (systolic blood pressure =160mmHg or diastolic blood pressure =100mmHg); 9. pregnant or lactating women.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Laboratory analysis of samples
Laboratory analysis of samples

Locations

Country Name City State
China Ethics Committee of Shanghai Renji Hospital Shanghai Shanghai

Sponsors (14)

Lead Sponsor Collaborator
RenJi Hospital Changzhou No.2 People's Hospital, First Affiliated Hospital of Fujian Medical University, First Affiliated Hospital, Sun Yat-Sen University, Fudan University, Jiangxi Provincial People's Hopital, Peking University First Hospital, Ruijin Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai 10th People's Hospital, Shanghai Zhongshan Hospital, Tongji Hospital, Zhejiang Provincial People's Hospital, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Systemic treatment OS Systemic treatment OS was defined as the time from the start of systemic treatment to death from any cause, and patients without a recorded death were right censored to the date of last clinical visit or clinical record. Through study completion, an average of 3 year
Secondary First-line PFS First-line progression free survival (PFS) was defined as the time from the start of first-line systemic treatment to the time of radiographic progression, or death from any cause, whichever occurred first. Through study completion, an average of 3 year
Secondary ORR Objective response rate (ORR) was defined as complete response (CR)+ partial response (PR) Through study completion, an average of 3 year
Secondary DCR disease control rate (DCR) was defined as partial response (PR)+complete response (CR)+stable disease (SD) Through study completion, an average of 3 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Recruiting NCT05548933 - Effects of Non-surgical Periodontal Therapy on Severe Periodontitis and Hyperlipidemia
Active, not recruiting NCT03926572 - Acute Decompensation of Pulmonary Hypertension N/A
Recruiting NCT05372159 - Vanderbilt Memory and Aging Project
Completed NCT03173586 - Sugar Sweetened Beverage Intake and Biomarkers of Cardiometabolic Risk in US Women N/A
Completed NCT04554628 - Early Prediction of Acute Kidney Injury Among Patients Admitted to Surgical ICU N/A
Terminated NCT03250312 - The Effects of OMT on the Expression Patterns of Immune Cell Biomarkers N/A
Recruiting NCT04666766 - Detecting Traumatic Intracranial Hemorrhage With Microwaves and Biomarkers N/A
Completed NCT04573543 - The Role of Immune Semaphorins in NAFLD
Completed NCT03193671 - Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis N/A
Recruiting NCT06047132 - PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED SUBJECTS
Completed NCT05361460 - Patients Experiences of Early Postoperative Cognition
Recruiting NCT05706194 - Early Neuroprognostication After OHCA
Recruiting NCT05138731 - Metabolomics Profiling of Coronary Heart Disease
Recruiting NCT06446895 - Biomarkers of Inflammation and Endothelial Dysfunction in Patients With Myocardial Infarction With Non-obstructive Coronary Arteries
Not yet recruiting NCT04563000 - Impact of Vitamin C on Biomarkers of Neurologic Injury in Survivors of Cardiac Arrest Phase 2
Completed NCT05138692 - Biomarkers and Outcome 1 and 10-15 Years After Severe Traumatic Brain Injury
Completed NCT02247999 - Improving Cervical Cancer Screening Among HIV-Infected Women in India
Active, not recruiting NCT02732301 - Postoperative Gastrointestinal Dysfunction After Cardiac Surgery - Occurrence and Search for Biomarkers
Not yet recruiting NCT03269019 - Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia N/A